2003
Concurrent chemo-radiotherapy with mitomycinc (MC) compared to porfiromycin (PO) in squamous cell carcinoma of the head and neck (SCCHN): final results of a randomized clinical trial
Haffty B, Son Y, Wilson L, Cho E, Papac R, Fischer D, Rockwell S, Sartorelli A, Sasaki C, Fischer J. Concurrent chemo-radiotherapy with mitomycinc (MC) compared to porfiromycin (PO) in squamous cell carcinoma of the head and neck (SCCHN): final results of a randomized clinical trial. International Journal Of Radiation Oncology • Biology • Physics 2003, 57: s246. DOI: 10.1016/s0360-3016(03)01076-9.Peer-Reviewed Original Research
2002
Evaluation of Second Malignancy and Local Recurrence in Patients with T1 and T2 Squamo Cell Carcinoma (SCC) of the Larynx
Colasanto J, Wilson L, Haffty B. Evaluation of Second Malignancy and Local Recurrence in Patients with T1 and T2 Squamo Cell Carcinoma (SCC) of the Larynx. The Cancer Journal 2002, 8: 491. DOI: 10.1097/00130404-200211000-00035.Peer-Reviewed Original Research
2000
Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation
Yoo S, Carter D, Turner B, Sasaki C, Son Y, Wilson L, Glazer P, Haffty B. Prognostic significance of cyclin D1 protein levels in early‐stage larynx cancer treated with primary radiation. International Journal Of Cancer 2000, 90: 22-28. PMID: 10725854, DOI: 10.1002/(sici)1097-0215(20000220)90:1<22::aid-ijc3>3.0.co;2-t.Peer-Reviewed Original ResearchConceptsEarly-stage larynx cancerLocal relapsePrognostic significanceLarynx cancerTotal median dosePrimary radiation therapySquamous cell carcinomaCell nuclear antigen levelsParaffin-embedded specimensSignificant clinical implicationsCase-control designPercent distributionLarynx cancer patientsCyclin D1 protein levelsCyclin D1 levelsMedian doseControl patientsLocal recurrenceAntigen levelsCancer patientsCell carcinomaDaily fractionsRadiation therapyIndex caseClinical information
1997
Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck
Haffty B, Son Y, Wilson L, Papac R, Fischer D, Rockwell S, Sartorelli A, Ross D, Sasaki C, Fischer J. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. International Journal Of Cancer 1997, 5: 235-245. PMID: 9372546, DOI: 10.1002/(sici)1520-6823(1997)5:5<235::aid-roi4>3.0.co;2-z.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaWhite blood cell countPhase I trialCell carcinomaRadiation therapyMitomycin CNonhematological toxicitiesI trialStage III/IV squamous cell carcinomaCourse of RTTotal median doseAcceptable toxicity profilePhase III trialsCurrent ongoing trialsDisease survival ratesDaily radiation therapyBlood cell countHypoxic cell cytotoxinActuarial survivalHemoglobin nadirsAdvanced diseaseMedian doseIII trialsOngoing trialsMultiinstitutional trial
1996
2110 Porfiromycin as an adjunct to radiation therapy in squamous cell carcinoma of the head and neck
Haffty B, Son Y, Papac R, Fischer D, Wilson L, Rockwell S, Sartorelli A, Sasaki C, Fischer J. 2110 Porfiromycin as an adjunct to radiation therapy in squamous cell carcinoma of the head and neck. International Journal Of Radiation Oncology • Biology • Physics 1996, 36: 331. DOI: 10.1016/s0360-3016(97)85686-6.Peer-Reviewed Original Research
1995
Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation
Licata A, Wilson L, Braverman I, Feldman A, Kacinski B. Malignant Melanoma and Other Second Cutaneous Malignancies in Cutaneous T-Cell Lymphoma: The Influence of Additional Therapy After Total Skin Electron Beam Radiation. JAMA Dermatology 1995, 131: 432-435. DOI: 10.1001/archderm.1995.01690160060009.Peer-Reviewed Original ResearchTotal skin electron beam therapyCutaneous T-cell lymphomaT-cell lymphomaSquamous cell carcinomaBasal cell carcinomaElectron beam therapyAdditional radiation therapyCell carcinomaCutaneous malignanciesOral psoralenAdditional therapyMalignant melanomaRadiation therapyBeam therapyTotal skin electron beam radiationFurther radiation therapyGroup of patientsNonmelanoma skin cancerAnecdotal case reportsPrevious large studiesTopical mechlorethamineHydrochloride therapyCase reportPatientsCarcinoma